Regulatory Bayer gets swift review for Kerendia in type 1 diabetes PharmaphorumFDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.Metabolic & GLP-1Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaphorum FDA starts a priority review of Bayer’s Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPDNext: FUJIFILM opens new iPSC facility in Madison, US Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
